Organized by WDM Capital, Wedbush Europe, and Filipex
Enterprises, participating companies will discuss their innovative
technologies, current progress, and future opportunities through
corporate presentations and small group meetings. Over 100 leading
life sciences institutional investors, fund managers, and analysts
from Central and Eastern Europe are
expected to participate and assess new investment
opportunities.
A replay of the conference will be available on the company's
website by 4 pm
EDT on June 12,
2015: http://www.pressurebiosciences.com.
Mr. Andrew D.
Filipek, Vice Chairman of Wedbush Europe, said: "We are
pleased to again have Pressure BioSciences present at the Global
Life Science Conference in Warsaw. Although only in its
third year, the conference is already one of the largest life
sciences microcap conferences in Central Europe. The
organizers have assembled an impressive list of exciting microcap
life sciences companies and an equally impressive group of life
sciences investors. We believe many significant investment
opportunities will come from this forum inWarsaw, the financial capital
of Central and Eastern Europe, and a major
center of life sciences investment."
"PBI's patented pressure cycling technology ("PCT") is an
innovative, transformative technology platform that has the
potential to significantly improve life sciences research
worldwide," commented Mr. Wojciech
Gudaszewski, CEO and Founder of WDM Capital. "The
Company has shown impressive technological and operational growth
over the past few years. We believe that PBI's second appearance on
Polish soil will continue the journey it began last October at the
2nd Global Conference, when Central and Eastern
European investors first learned of the uniqueness and versatility
of PBI's PCT Platform. We are pleased to have them present
again this year, as we believe there are exciting and rewarding
growth opportunities of mutual benefit in Poland."
Mr. Richard T.
Schumacher, President and CEO of PBI, said: "We are very
appreciative of the invitation to present an overview of PBI to
such an impressive group of European investors. It is even
more special knowing that the venue is the floor of the Warsaw
Stock Exchange, the largest national financial instruments exchange
in the region of Central and Eastern Europe and one of the
fastest-growing exchanges in all of Europe. We look forward
to presenting on the potential of PBI and on the measurable
progress we have made since our presentation last October. We
also look forward to the group and one-on-one interactions that
have been planned with investors, which will allow us the
opportunity to discuss how we might work together to mutual
benefit."
About Pressure BioSciences, Inc.
Pressure BioSciences, Inc. ("PBI") (OTCQB: PBIO) develops, markets,
and sells proprietary laboratory instrumentation and associated
consumables to the estimated $6 billion life sciences
sample preparation market. Our products are based on the unique
properties of both constant (i.e., static) and alternating (i.e.,
pressure cycling technology, or PCT) hydrostatic pressure. PCT is a
patented enabling technology platform that uses alternating cycles
of hydrostatic pressure between ambient and ultra-high levels to
safely and reproducibly control bio-molecular interactions. To
date, we have installed over 250 PCT systems in approximately 160
sites worldwide. There are over 100 publications citing the
advantages of the PCT platform over competitive methods, many from
key opinion leaders. Our primary application development and sales
efforts are in the biomarker discovery and forensics areas.
Customers also use our products in other areas, such as drug
discovery & design, bio-therapeutics characterization, soil
& plant biology, vaccine development, histology, and
counter-bioterror
applications.
Forward Looking Statements
Statements contained in this press release regarding PBI's
intentions, hopes, beliefs, expectations, or predictions of the
future are "forward-looking'' statements within the meaning of the
Private Securities Litigation Reform Act of 1995. These statements
are based upon the Company's current expectations, forecasts, and
assumptions that are subject to risks, uncertainties, and other
factors that could cause actual outcomes and results to differ
materially from those indicated by these forward-looking
statements. These risks, uncertainties, and other factors include,
but are not limited to, the risks and uncertainties discussed under
the heading "Risk Factors" in the Company's Annual Report on Form
10-K for the year ended December 31, 2014, and other
reports filed by the Company from time to time with the SEC. The
Company undertakes no obligation to update any of the information
included in this release, except as otherwise required by law.
For more information about PBI and this press release, please
click on the following website link: http://www.pressurebiosciences.com
Please visit us on Facebook, LinkedIn, and Twitter
Investor Contacts:
Richard T.
Schumacher, President and CEO (508) 230-1828
(T)
Jeffrey N.
Peterson, Chairman (650) 812-8121 (T)
To view the original version on PR Newswire, visit:http://www.prnewswire.com/news-releases/pressure-biosciences-inc-to-present-at-the-3rd-global-life-sciences-conference-in-warsaw-poland-300097710.html
SOURCE Pressure BioSciences, Inc.
Copyright © 2015 PR Newswire. All Rights Reserved
The above news release has been provided by the above company
via the OTC Disclosure and News Service. Issuers of news releases
and not OTC Markets Group Inc. are solely responsible for the
accuracy of such news releases.